April 10 (Reuters) - ADVICENNE SA ADVIC.PA :
* FY REVENUE EUR 0.6 MILLION VERSUS EUR 0.3 MILLION YEAR AGO
* FY OPERATING LOSS EUR 6.0 MILLION VERSUS LOSS EUR 3.2
MILLION
YEAR AGO
* FY NET LOSS EUR 6.0 MILLION VERSUS LOSS EUR 3.6 MILLION
YEAR AGO
* PLANS TO LAUNCH TWO PIVOTAL STUDIES WITH ADV7103 IN 2018
* ADV7103: PLANS TO LAUNCH IN H2 PHASE II/III PIVOTAL
CLINICAL
TRIAL IN US IN DRTA PATIENTS
* ADV7103: PLANS TO LAUNCH IN H1 PHASE II/III PIVOTAL
CLINICAL
TRIAL IN EUROPE IN CYSTINURIA PATIENTS
* CASH AND CASH EQUIVALENTS AT END-DEC. EUR 36.2 MILLION
Source text : https://bit.ly/2HqTIoD
Further company coverage: ADVIC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 59 772 0920;))